#None #Kessler Topaz #Securities Fraud #uniQure N.V.

Kessler Topaz Meltzer & Check LLP Takes Action Against uniQure N.V.

In a significant move for investors, Kessler Topaz Meltzer & Check, LLP has initiated a class action lawsuit against uniQure N.V. (NASDAQ: QURE) pertaining to alleged securities fraud. The lawsuit was filed on behalf of all individuals who purchased or acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025—a period referred to as the Class Period. The case is officially titled Scocco v. uniQure N.V., et al., Case No. 126-cv-01124, and is being heard in the United States District Court for the Southern District of New York.

Key Details of the Allegations

Date of Filing

The action, prompting attention within the investment community, was filed recently, with a reminder that the deadline for investors wishing to be established as lead plaintiffs is April 13, 2026. This date is crucial for those who wish to represent the interests of the class of affected investors in court.

Allegations of Misconduct

The central allegations against uniQure revolve around significant misstatements and failures to disclose essential facts regarding their gene therapy for Huntington's disease (HD), specifically the drug candidate AMT-130. The lawsuit argues that the company misled investors regarding its Phase I/II clinical trials, known as the Pivotal Study, as well as the timeline associated with its Biologics License Application (BLA) to the FDA.

The complaint highlights that during the Class Period, defendants of uniQure failed to accurately represent the approval status of the Pivotal Study design and downplayed serious risks related to the inevitable postponement of the BLA timeline due to the necessity for additional studies. Instead, the company made optimistic public claims, which have now been depicted as lacking any reasonable basis after the true situation was revealed to investors.

A Dramatic Share Price Decline

Investors faced a harrowing experience when, on November 3, 2025, uniQure disclosed that the FDA had expressed reservations about the adequacy of data from AMT-130's clinical trials to support the BLA submission. The news led to a catastrophic drop of over 49% in the company's share price—from $67.69 on October 31, 2025, to $34.29 just two days later. This dramatic plunge highlighted the severe ramifications of the alleged securities fraud and the impact on investor confidence.

Taking Steps Forward

For affected investors, there are clear courses of action. They may seek to become lead plaintiffs by filing their motion by the stipulated deadline. Furthermore, Kessler Topaz Meltzer & Check, LLP is facilitating no-cost consultations to discuss potential recovery options for those who have incurred losses due to their investments in uniQure.

Contact Information

Investors desiring legal representation or advice are encouraged to contact Jonathan Naji, Esq., at (484) 270-1453 or via email at [email protected]. The firm reassures potential clients that discussions regarding their cases come without any obligation.

About Kessler Topaz Meltzer & Check, LLP

Founded with a commitment to protecting investors' rights, Kessler Topaz Meltzer & Check has established itself as a formidable legal entity in the realm of securities litigation. The firm has achieved notable success, recovering over $25 billion for its clients and earning recognition from prominent legal publications. Their expertise lies in helping both individual and institutional investors navigate complex securities fraud cases.

In summary, the ramifications of the lawsuit filed against uniQure N.V. accentuate the critical importance of transparency in the biotech sector and the overarching need for investor vigilance. Stakeholders should stay informed and act decisively, particularly in light of significant developments in the case that could influence the outcome for affected shareholders.